title: Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer's disease and dementia with Lewy bodies.
abstract: OBJECTIVE
  To investigate normalized I-5-Iodo-3-[2(S)-2-azetidinylmethoxy] pyridine (5IA-85380) single photon emission computed tomography (SPECT) imaging, a marker for the alpha4beta2 nicotinic receptor, as a predictor of cognitive progression in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
  
  
  METHODS
  Thirty-one patients with dementia (16 patients with AD and 15 patients with DLB) underwent I-5IA-85380 SPECT scanning. Image analysis was performed using statistical parametric mapping (SPM2), which involved spatial preprocessing of scans to standard Montreal Neurological Institute space and intensity normalization of each image to its mean global brain activity.
  
  
  RESULTS
  Regression analysis revealed that reduced normalized I-5IA-85380 uptake in left superior, middle, and inferior frontal gyri and prepost central and anterior cingulate regions significantly correlated with decline in executive function in a pooled group comprising AD and DLB.
  
  
  CONCLUSIONS
  The findings, although preliminary, suggest that the cholinergic system may be more involved in neurodegenerative processes affecting some cognitive processes more than others, as such, this procedure may be useful for increased understanding of the pathophysiological mechanisms responsible for neurodegeneration.
authors.affiliation: Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, United Kingdom. s.j.colloby@ncl.ac.uk
authors.forename: Sean J
authors.initials: SJ
authors.lastname: Colloby
authors.forename: Elaine K
authors.initials: EK
authors.lastname: Perry
authors.forename: Sanjeet
authors.initials: S
authors.lastname: Pakrasi
authors.forename: Sally L
authors.initials: SL
authors.lastname: Pimlott
authors.forename: David J
authors.initials: DJ
authors.lastname: Wyper
authors.forename: Ian G
authors.initials: IG
authors.lastname: McKeith
authors.forename: E David
authors.initials: ED
authors.lastname: Williams
authors.forename: John T
authors.initials: JT
authors.lastname: O'Brien
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000523:psychology*; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000000981:diagnostic imaging; D001384:Azetidines; D001931:Brain Mapping / Q000379:methods; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism*; D003072:Cognition Disorders / Q000175:diagnosis* / Q000000981:diagnostic imaging; D018450:Disease Progression; D056344:Executive Function; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000000981:diagnostic imaging; D008297:Male; D011725:Pyridines; D011978:Receptors, Nicotinic / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: C426745:5-iodo-3-(2-azetidinylmethoxy)pyridine; D001384:Azetidines; D007457:Iodine Radioisotopes; D011725:Pyridines; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2